Literature DB >> 28299619

Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A.

Tomoki Ryu1, Yuko Takami2, Yoshiyuki Wada2, Masaki Tateishi2, Hajime Matsushima2, Kazuhiro Mikagi2, Hideki Saitsu2.   

Abstract

The prognostic implications of the expression patterns of three tumor markers, alpha-fetoprotein (AFP), the Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxy prothrombin (DCP), have been evaluated in patients with hepatocellular carcinoma (HCC). From January 1994 to December 2014, 1182 consecutive patients underwent hepatic resection and surgical microwave ablation for HCC at our institution. This study analyzed 475 patients within the Milan criteria and Child-Pugh class A. Cumulative overall survival (OS) and disease-free survival (DFS) rates were analyzed relative to the number of positive tumor markers. OS and DFS at 5 years postoperatively were 85.3 and 44.2% in triple-negative patients, 79.4 and 48.0% in single-positive patients, 56.2 and 32.9% in double-positive patients, and 61.7 and 35.7% in triple-positive patients with statistical significance. OS in triple-negative or single-positive patients was 85.3%, and that in all double- or triple-positive patients was 58.0% (P < 0.0001); DFS at 5 years postoperatively in these two groups was 45.9 and 34.0%, respectively (P < 0.0013). Both double- and triple-positive tumor markers are associated with early recurrence and poor survival in HCC patients within the Milan criteria and Child-Pugh class A.

Entities:  

Keywords:  Alfa-fetoprotein; Des-γ-carboxy prothrombin; Hepatocellular carcinoma; Microwave ablation; Protein induced by vitamin K absence/antagonist-II

Mesh:

Substances:

Year:  2017        PMID: 28299619     DOI: 10.1007/s11605-017-3394-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

2.  Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akihiro Yamaguchi; Masatoshi Isogai; Yuji Kaneoka; Junji Washizu
Journal:  Clin Gastroenterol Hepatol       Date:  2006-01       Impact factor: 11.382

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

5.  Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival.

Authors:  Shigehisa Kiriyama; Kazuhisa Uchiyama; Masaki Ueno; Satoru Ozawa; Shinya Hayami; Masaji Tani; Hiroki Yamaue
Journal:  Ann Surg       Date:  2011-12       Impact factor: 12.969

6.  Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.

Authors:  Masakuni Tateyama; Hiroshi Yatsuhashi; Naota Taura; Yasuhide Motoyoshi; Shinya Nagaoka; Kenji Yanagi; Seigo Abiru; Koji Yano; Atsumasa Komori; Kiyoshi Migita; Minoru Nakamura; Hiroyasu Nagahama; Yutaka Sasaki; Yuzo Miyakawa; Hiromi Ishibashi
Journal:  J Gastroenterol       Date:  2010-08-14       Impact factor: 7.527

7.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

Authors:  Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

9.  Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization.

Authors:  Toshiya Kamiyama; Kazuaki Nakanishi; Hideki Yokoo; Hirofumi Kamachi; Munenori Tahara; Tomomi Suzuki; Tsuyoshi Shimamura; Hiroyuki Furukawa; Michiaki Matsushita; Satoru Todo
Journal:  Ann Surg Oncol       Date:  2009-03-04       Impact factor: 5.344

Review 10.  Microwave ablation of hepatocellular carcinoma.

Authors:  Ping Liang; Yang Wang
Journal:  Oncology       Date:  2007-12-13       Impact factor: 2.935

View more
  4 in total

1.  Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade.

Authors:  Hajime Matsushima; Yuko Takami; Tomoki Ryu; Munehiro Yoshitomi; Masaki Tateishi; Yoshiyuki Wada; Hideki Saitsu
Journal:  J Gastrointest Surg       Date:  2018-05-07       Impact factor: 3.452

2.  A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria.

Authors:  Tomoki Ryu; Yuko Takami; Yoshiyuki Wada; Masaki Tateishi; Takanobu Hara; Munehiro Yoshitomi; Seiya Momosaki; Kotaro Yasumori; Hideki Saitsu; Koji Okuda
Journal:  J Gastrointest Surg       Date:  2019-02-20       Impact factor: 3.452

3.  APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.

Authors:  Tatsuo Kanda; George K K Lau; Lai Wei; Mitsuhiko Moriyama; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geoffrey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Yoshihiko Ooka; Osamu Yokosuka; Shiv Kumar Sarin; Masao Omata
Journal:  Hepatol Int       Date:  2019-09-20       Impact factor: 6.047

4.  Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.

Authors:  Shun Kaneko; Masayuki Kurosaki; Kaoru Tsuchiya; Yutaka Yasui; Yuka Hayakawa; Kento Inada; Yuki Tanaka; Shun Ishido; Sakura Kirino; Koji Yamashita; Tsubasa Nobusawa; Hiroaki Matsumoto; Tatsuya Kakegawa; Mayu Higuchi; Kenta Takaura; Shohei Tanaka; Chiaki Maeyashiki; Nobuharu Tamaki; Yuka Takahashi; Hiroyuki Nakanishi; Namiki Izumi
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.